ClinicalTrials.gg
Not yet recruitingNCT07848321Updated Sep 30, 2026

Risk Factors and Outcomes of Hepatitis A in Children

An observational study in Hepatitis A and Acute Hepatitis, sponsored by Assiut University. Not yet recruiting. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Assiut University · Observational

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
190
Ages
1 Month to 18 Years
Sex
All
01

Study summary

This prospective observational study aims to evaluate the risk factors, clinical course, and outcomes among children with acute hepatitis A infection admitted to Assiut University Children Hospital.

Read the detailed description

Hepatitis A virus infection is a common cause of acute hepatitis in children in Egypt. While most cases recover completely, some children may develop complications such as prolonged cholestasis, acute liver failure, or hepatic encephalopathy.

This observational study will include children aged 1 month to 18 years with confirmed acute hepatitis A infection (positive Anti-HAV IgM). Patients will be followed during their hospital stay to assess clinical course and outcomes.

02

Conditions studied

  • Hepatitis A
  • Acute Hepatitis

Keywords

  • Hepatitis A
  • Assiut
  • Children
  • Acute liver failure
03

In context

Hepatitis A

82 studies on the registry are indexed under Hepatitis A; 9 are open to participants now.

This study's planned enrollment of 190 is below the median of 466 across 18 observational studies indexed under Hepatitis A.

Browse Hepatitis A studies →

Lead sponsor

Assiut University is the lead sponsor of 5,081 studies on the registry; 2,179 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children with confirmed acute hepatitis A infection admitted to or presenting at Assiut University Children Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 1 month to 18 years
  • Confirmed acute hepatitis A infection by positive Anti-HAV IgM
  • Written from parents or legal guardians

Exclusion criteria

Exclusion Criteria:

  • - Co-infection with , , or hepatitis E
  • Chronic liver diseases ( hepatitis, Wilson disease, metabolic liver diseases)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
190 participants (estimated)
Patient registry
No

Groups and cohorts

  • Single cohort: Children with acute hepatitis A

    Children aged 1 month to 18 years with confirmed acute hepatitis A infection who will be followed during hospital stay to assess clinical course and outcomes.

06

What researchers measure

Primary outcomes

  1. Proportion of children with unfavorable outcome

    Proportion of children who develop one or more of the following during hospital stay: acute liver failure, hepatic encephalopathy, acute kidney injury, ICU admission, prolonged hospital stay (\>7 days), or death.

    Time frame: Baseline

Secondary outcomes

  1. Proportion of children with acute liver failure

    Proportion of children who develop acute liver failure during hospital stay.

    Time frame: Baseline

  2. Proportion of children with hepatic encephalopathy

    Proportion of children who develop hepatic encephalopathy (any West Haven grade) during hospital stay.

    Time frame: Baseline

  3. Mean duration of hospital stay

    Mean number of days of hospitalization.

    Time frame: Baseline

  4. Proportion of children requiring ICU admission

    Proportion of children who require intensive care unit admission.

    Time frame: Baseline

  5. Mortality rate

    Proportion of children who die during hospital stay.

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 30, 2026
StartEst.
Sep 26, 2026
Primary completionEst.
Sep 26, 2027
CompletionEst.
Mar 25, 2028
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07848321
Lead sponsor
Assiut University
Responsible party
Nada Ashraf Fouad (Resident Physician, Department of Pediatrics, Assiut University) — Principal investigator
First posted
Sep 30, 2026
Start date
Sep 26, 2026 (estimated)
Primary completion
Sep 26, 2027 (estimated)
Completion
Mar 25, 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Nada A Fouad, Resident
Contact
Nada.17289945@med.aun.edu.eg
+20 11 18762071
Ahlam B Ali, prof
study chair · Pediatrics Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion